



August 1, 2025

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub: Unaudited Financial Results for the quarter ended June 30, 2025**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 10.04 a.m. and ended at 13:47 p.m.), the Unaudited Financial Results for the quarter ended June 30, 2025 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended June 30, 2025;
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended June 30, 2025 furnished by Statutory Auditors of the Company.

Kindly take the same on record and oblige.

Thanking you.

For **Procter & Gamble Health Limited**

**Zeal Rupani**  
Company Secretary

**PROCTER & GAMBLE HEALTH LIMITED**

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.  
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025**

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)
		Three months ended 30th June 2025  (Unaudited)	Preceding Three months ended 31st March 2025  (Audited) (refer note 4)	Corresponding Three months ended 30th June 2024  (Audited) (refer note 4)	Previous Year (Nine Months) ended 31st March 2025  (Audited) (refer note 3)
1.	Revenue from Operations	33 874	31 099	28 388	93 417
2.	Other Income	403	311	213	1 035
3.	<b>Total income (1+2)</b>	<b>34 277</b>	<b>31 410</b>	<b>28 601</b>	<b>94 452</b>
	<b>Expenses</b>				
	a) Cost of materials consumed	5 954	9 082	6 742	20 059
	b) Purchases of stock-in-trade (Traded goods)	2 431	1 372	1 851	4 716
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	1 014	( 582)	( 676)	1 475
	d) Employee benefits expenses	5 601	4 879	4 863	14 206
	e) Depreciation and amortisation expenses	544	537	716	1 669
	f) Finance costs	12	13	20	43
	g) Other expenses	9 840	8 256	10 783	21 122
4.	<b>Total expenses (4)</b>	<b>25 396</b>	<b>23 557</b>	<b>24 299</b>	<b>63 290</b>
5.	<b>Profit before exceptional items and tax (3-4)</b>	<b>8 881</b>	<b>7 853</b>	<b>4 302</b>	<b>31 162</b>
6.	Less: Exceptional items (refer note 7)	-	-	2 019	-
7.	<b>Profit before tax (5-6)</b>	<b>8 881</b>	<b>7 853</b>	<b>2 283</b>	<b>31 162</b>
8.	<b>Tax expenses</b>				
	a) Current Tax	2 294	2 064	1 279	7 763
	b) Deferred Tax Charge / (Credit)	( 31)	( 336)	( 674)	( 49)
	c) Adjustment of tax relating to earlier periods	-	7	-	7
	<b>Total tax expenses</b>	<b>2 263</b>	<b>1 735</b>	<b>605</b>	<b>7 721</b>
9.	<b>Net Profit for the period / year (7-8)</b>	<b>6 618</b>	<b>6 118</b>	<b>1 678</b>	<b>23 441</b>
10.	<b>Other Comprehensive Income</b>				
	Items that will not be reclassified to profit or loss				
	i. Re-measurement gains / (losses) on defined benefit plans	( 87)	( 107)	( 134)	( 350)
	ii. Income tax effect on above	22	27	33	88
	<b>Other Comprehensive Income, net of tax</b>	<b>( 65)</b>	<b>( 80)</b>	<b>( 101)</b>	<b>( 262)</b>
11.	<b>Total Comprehensive Income for the period / year (9+10)</b>	<b>6 553</b>	<b>6 038</b>	<b>1 577</b>	<b>23 179</b>
12.	Paid-up equity share capital (Face Value ₹ 10/- each)	1 660	1 660	1 660	1 660
13.	Other equity				52 036
14.	<b>Earnings per equity share (of ₹ 10/- each)</b> <b>*(not annualised)</b>				
	(a) Basic and Diluted (in ₹) (before exceptional items)	* 39.87	* 36.86	* 22.27	141.22
	(b) Basic and Diluted (in ₹) (after exceptional items)	* 39.87	* 36.86	* 10.11	141.22

## PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.  
CIN No. L99999MH1967PLC013726, email: investor@grievance.im@pg.com

### Notes:

1. The above unaudited financial results for the quarter ended June 30, 2025 have been reviewed by Audit Committee and approved by Board of directors of the Company at meeting held on August 1, 2025. The Statutory auditors of the company have carried on limited review of the above unaudited financial results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an unmodified conclusion.
2. This Statement has been prepared in accordance with the Companies ("Indian Accounting Standards") Rules, 2015 ("IND AS") prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the previous Financial Year of the Company viz., 2024-25 is for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025.
4.
  - a. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of nine months financial year ended March 31, 2025 and the limited reviewed year to date figures up to six months period ended December 31, 2024 of the nine months Financial Year ended March 31, 2025.
  - b. The figures for the quarter ended June 30, 2024 are the balancing figures between audited figures in respect of twelve months financial year ended June 30, 2024 and the limited reviewed year to date figures up to nine months period ended March 31, 2024 of the twelve months Financial Year ended June 30, 2024.
5. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
6. The unaudited financial results are available on the website of the Company ([www.pghealthindia.com](http://www.pghealthindia.com)) and on the websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
7. During the quarter ended June 30, 2024, the Company had discontinued production of injections at its manufacturing plant in Goa effective September 30, 2023, as the Company had started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter ended June 30, 2024, the Company had entered into an agreement for sale of the assets of its injection plant for a consideration of ₹ 790 Lakhs and impaired the balance amount of ₹ 627 Lakhs. Based on above, the company had re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount of ₹ 1 392 Lakhs. The above total amount of ₹ 2 019 Lakhs was disclosed as an exceptional item for the quarter year ended June 30, 2024.
8. Previous year's/period's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's classification.
9. The Company does not have a subsidiary, an associate or a joint venture as at 30th June, 2025.

For and on behalf of the Board of Directors of  
Procter & Gamble Health Limited

**Milind Vasant**  
**Thatte**  
Digitally signed by  
Milind Vasant Thatte  
Date: 2025.08.01  
13:23:08 +05'30'  
Milind Thatte  
Managing Director

Place : Mumbai  
Date : August 01, 2025

# HARIBHAKTI & CO. LLP

Chartered Accountants

**Independent Auditor's Review Report on quarterly Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)**

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# HARIBHAKTI & CO. LLP

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048



Sumant Sakhardande  
Partner  
Membership No. 034828



UDIN: 25034828BMNZJX9050

Place: Mumbai

Date: August 1, 2025